



Kodiak Sciences Inc. Announces Closing of Initial Public Offering

October 10, 2018 at 7:00 AM EDT

PALO ALTO, Calif., Oct. 10, 2018 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD) today announced the closing on October 9, 2018 of its initial public offering of 9,000,000 shares of common stock at a price to the public of \$10.00 per share. The gross proceeds to Kodiak, before deducting underwriting discounts and commissions and offering expenses, were \$90 million. The shares began trading on The Nasdaq Global Market under the ticker symbol "KOD" on October 4, 2018.

Morgan Stanley and BofA Merrill Lynch acted as joint book-running managers for the offering. Barclays also acted as a book-running manager for the offering. Chardan acted as lead manager.

The offering was made only by means of a prospectus. A copy of the final prospectus may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or [email dg.prospectus_requests@baml.com](mailto:email_dg.prospectus_requests@baml.com); or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or [email barclaysprospectus@broadridge.com](mailto:email_barclaysprospectus@broadridge.com).

A registration statement relating to the offering has been filed with the Securities and Exchange Commission and was declared effective on October 3, 2018. Copies of the registration statement can be accessed through the SEC's website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

About Kodiak Sciences Inc.

Kodiak Sciences Inc. is a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases.

 View original content to download multimedia: <http://www.prnewswire.com/news-releases/kodiak-sciences-inc-announces-closing-of-initial-public-offering-300728366.html>

SOURCE Kodiak Sciences Inc.

John Borgeson, Senior Vice President and Chief Financial Officer, Tel (650) 281-0850, media@kodiak.com